PACTR202008836432905已完成1 期
A Phase I/II, Double-blind, Randomized, Active-controlled, Age De-escalation Trial to Assess Safety and Immunogenicity of a Measles Rubella Vaccine (MRV) Microneedle Patch (MRV-MNP) in Adults, MRV-primed Toddlers, and MRV-naïve Infants
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 285
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 Month(s) 至 23 Month(s)（—）
- 性别
- All
入选标准
- •Adults: Be between 18 and 40 years inclusive on the day of consent.
- •Toddlers: Be between 15 and 18 months of age inclusive on the day of consent.
- •Infants: Be between 9 and 10 months of age inclusive on the day of consent.Be judged to be able to comprehend and comply with study requirement and procedures and must be willing and able to return for all scheduled follow-up visits (adult cohort).
- •Have a parent who is judged to be able to comprehend and comply with study requirement and procedures and is willing and able to return for all scheduled follow-up visits (toddler and infant cohort).
- •Be willing to avoid consumption (ingestion and topical application) of herbal or other local traditional medications throughout the course of the study.
- •Have a readily identifiable place of residence within a reasonable travelling distance of the clinical trial site.
- •Have a consistent means of telephone contact for the duration of trial participation
- •Have a site on one wrist that is judged to be suitable for MNP administration.
- •Adult female cohort only: have a negative serum pregnancy test at screening (V0) and negative urine pregnancy test on the day of vaccination (V1).
- •Adult female cohort only: employ an effective method of birth control for two months preceding and throughout the study
- •Toddler cohort only: have been parenterally vaccinated against measles and rubella at between nine and 12 months of age.
排除标准
- •Have used any investigational product within the 90 days prior to study product administration or plan to use any investigational products during the period of study participation.
- •Have consumed (by ingestion or topical application) any herbal or other traditional medication within 14 days of study product administration
- •Have a history of serious reactions to any prior vaccination or known hypersensitivity to any component of the MRV-MNP, MRV-SC or PLA-MNP including polyethylene foam with acrylic adhesive, silicone-coated Kraft paper, stainless steel, and severe allergic reactions to cow's milk.
- •Have a history of anaphylactic shock or other life-threatening allergic reactions
- •Have any chronic, clinically significant pulmonary, cardiovascular, hepatobiliary, gastrointestinal, renal, neurological, or haematological abnormality or illness that requires medical therapy.
- •Have a history of administration of any non-study vaccines within the 56 days before the administration of study products or planned vaccination during study participation, except for non-measles and rubella catch-up/national campaign administered through the Gambian Ministry of Health.
- •Have a history of chronic administration (defined as more than 14 consecutive days) of immunosuppressant (> 0.5mg/kg/day of prednisolone or equivalent) or other immune modifying drugs within the 12 months prior to the administration of the study vaccine including the use of glucocorticoids. The use of inhaled/per nasal glucocorticoids will be permitted. The use of topical glucocorticoids within 12 months is not permitted.
- •Have a history of the administration of immunoglobulins and/or any blood products within the 12 months prior to administration of the study vaccine or anticipation of such administration during the study period.
- •Have a history of known disturbance of coagulation or blood disorder that could cause anaemia or excess bleeding (e.g. sickle cell disorders, thalassemia, and coagulation factor deficiencies).
研究者
相似试验
招募中
1 期
Phase 2 study comparing INBRX-101 to plasma-derived A1PI therapy for AATD emphysemaAlpha-1 Antitrypsin Deficiency (AATD) EmphysemaMedDRA version: 23.1Level: LLTClassification code: 10001806Term: Alpha-1 anti-trypsin deficiency Class: 10010331CTIS2023-508084-76-00Inhibrx Inc.94
进行中（未招募）
1 期
A Proof-of-concept Study of the Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitislcerative ColitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2018-001510-15-PLJanssen-Cilag International NV210
进行中（未招募）
1 期
A Proof-of-concept Study of the Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitislcerative ColitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2018-001510-15-DEJanssen-Cilag International NV210
进行中（未招募）
1 期
A Phase IIb/III, Double-Blind, Randomised, Active-Controlled, Multi-Center, Non-Inferiority Clinical Trial, to assess the safety and immunogenicity of a booster vaccination with an adapted recombinant protein RBD fusion homodimer candidate (PHH-1V81) against SARS-CoV-2, in adults vaccinated against COVID-19.CTIS2023-508458-25-00Hipra Scientific S.L.612
进行中（未招募）
1 期
A study comparing immunotherapy combinations with chemotherapy and chemotherapy alone in participants with advanced LAG-3 positive gastric and gastroesophageal junction (GEJ) cancersEUCTR2017-004896-30-NLBristol-Myers Squibb International Corporation2,420